


| Key | % Net Assets |
|---|---|
| 6.9% | |
| 5.5% | |
| 5.1% | |
| 5.0% | |
| 77.5% |
| Name | % Net Assets |
|---|---|
| AstraZeneca | 6.9% |
| Vodafone Group | 5.5% |
| Resolution | 5.1% |
| GlaxoSmithKline | 5.0% |
| BP | 5.0% |
| Rentokil Initial | 4.1% |
| Morrison Supermarkets | 4.0% |
| Lloyds Banking Group | 3.8% |
| Royal Bank of Scotland Group | 3.5% |
| Barclays | 3.4% |
| Key | % Net Assets |
|---|---|
| 30.30% | |
| 18.30% | |
| 17.60% | |
| 10.20% | |
| 7.90% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 175.60p |
| Currency | GBP |
| Change | 0.100p |
| % | 0.06% |
| YTD change | 21.60p |
| YTD % | 14.03% |
| Fund Inception | 04/11/2005 |
|---|---|
| Fund Manager | Thomas See |
| TER | 1.66 (28-Feb-2012) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.16 |
You are here: research